Former Anvisa Leaders Critique Proposal for Selling Medicines in Supermarkets
Former presidents of the National Health Surveillance Agency (Anvisa) have voiced strong opposition to a proposal allowing the sale of over-the-counter medications in supermarkets. This suggestion, brought forth by supermarket associations, aims to lower drug prices but raises significant health concerns.
Gonzalo Vecina and Claudio Maierovitch, both ex-leaders of Anvisa, shared their insights during interviews, emphasizing the potential risks associated with this initiative. They argue that placing medications on supermarket shelves could blur the lines between essential medical treatments and everyday consumer products.
Maierovitch highlighted that even non-prescription medicines can pose health risks if misused. He stressed the importance of having trained pharmacists available to provide guidance during the sale of these products. Without proper oversight, there's a danger that consumers may treat medications as casual purchases akin to groceries, which could lead to improper use.
In response to the proposal, the Brazilian Supermarket Association (Abras) has stated that they would hire pharmacists to assist shoppers, mirroring practices already seen in online pharmacy sales. This move aims to alleviate concerns regarding consumer safety and ensure proper usage of medications.
Vecina also reiterated the critical stance against the proposal, stating that while some non-pharmaceutical items could be sold in supermarkets, medications should be confined to pharmacies to maintain necessary health standards. He voiced concerns over the sanitary conditions required for the sale of medications, which necessitate stringent regulatory oversight.
In late 2024, Anvisa expressed its disapproval of the idea, pointing out that the sale of medicines in supermarkets raises significant sanitary concerns throughout the product's lifecycle, from production to consumption. The agency emphasized that medications require meticulous health controls.
As discussions progress, the debate continues between supermarket representatives and pharmacy associations, with each side presenting arguments regarding the implications of such a policy shift. Proponents argue that this change could enhance accessibility and affordability of medications, while opponents warn against the potential health risks that could arise from a less regulated environment.
The ongoing dialogue reflects broader concerns regarding the intersection of public health, consumer access, and regulatory frameworks, and it remains to be seen how these discussions will unfold in the coming months.
